Dihexa
Status
No approved product. No FDA-approved labeling exists. No human study is listed in this site's sources, and no approval elsewhere is listed in this site's sources.
What it is
An angiotensin-derived molecule studied in animals for synapse formation.
What published research measured
A small molecule derived from angiotensin IV, developed at Washington State University and reported in preclinical work to be a potent facilitator of hepatocyte growth factor signalling at its c-Met receptor, with animal studies describing enhanced synapse formation and reversal of cognitive deficits in rodent models of Alzheimer's disease. The reported potency figures are striking and are the reason the compound circulates. No published human trial of dihexa was identified for this entry, so it has no human efficacy, pharmacokinetic or safety data to show. The mechanism itself warrants caution rather than enthusiasm in the absence of that data: hepatocyte growth factor and c-Met signalling promote cell growth and are implicated in the progression of several cancers, and this entry cites no published human oncological safety assessment of a potent systemic agonist like this one.
Source
Ho JK et al. 2018 — Cognitive benefits of angiotensin IV and angiotensin-(1-7): A systematic review of experimental studies · McCoy AT et al. 2013 — Evaluation of metabolically stabilized angiotensin IV analogs as procognitive/antidementia agents · Nowotarska SW et al. 2014 — Effect of structure on the interactions between five natural antimicrobial compounds and phospholipids of bacterial c…
Sources
No linked primary source is on file for this entry yet.
Educational use only, never medical advice. No doses.